<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Haloperidol - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Haloperidol</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../index.html">Home</a>
        <a class="btn small" href="../medications.html">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Neuro / Psych</div>
      <h1>Haloperidol</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Haloperidol 1mg Tablets</li>
          <li>Haloperidol 5mg/mL Injection 1mL</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Acute agitation / acute psychosis (oral)</strong>
            <ul>
              <li>0.5–5 mg PO; may repeat every 4–8 hours as needed based on response and tolerability</li>
              <li>Start low (0.5–2 mg) in elderly or debilitated patients</li>
              <li>Typical effective dose range: 1–5 mg per dose</li>
            </ul>
          </li>
          <li><strong>Acute agitation / acute psychosis (IM)</strong>
            <ul>
              <li>2–5 mg IM; may repeat every 30–60 minutes as needed (reassess frequently)</li>
              <li>Use lower doses in elderly/debilitated patients (0.5–2 mg)</li>
              <li>Maximum: individualize; avoid excessive cumulative doses (QTc/EPS risk)</li>
            </ul>
          </li>
          <li><strong>Nausea/vomiting (refractory; when other agents inappropriate)</strong>
            <ul>
              <li>0.5–2 mg PO/IM every 6–8 hours as needed (off-label use; consult protocols)</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Acute agitation or acute psychotic symptoms (emergency management)</li>
          <li>Schizophrenia and other psychotic disorders (usually provider-directed chronic therapy; onboard use typically acute only)</li>
          <li>Severe behavioral disturbance requiring rapid control</li>
          <li>Refractory nausea/vomiting (off-label; when first-line agents unavailable or contraindicated)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity to haloperidol or butyrophenones</li>
          <li>CNS depression, coma</li>
          <li>Parkinson's disease or Lewy body dementia (can worsen extrapyramidal symptoms)</li>
          <li>QTc prolongation, cardiac arrhythmia risk, or concurrent QT-prolonging drugs (ECG monitoring ideal when available)</li>
          <li>Severe cardiovascular disease (monitor closely if used)</li>
          <li>Caution in elderly: increased risk of falls, sedation, extrapyramidal symptoms, and stroke/mortality in dementia patients (boxed warning)</li>
          <li>Hepatic impairment: use lower doses and monitor closely</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Extrapyramidal symptoms (EPS): dystonia, akathisia, parkinsonism (dose-related; may occur acutely)</li>
          <li>Sedation, drowsiness</li>
          <li>QTc prolongation, arrhythmia (especially at higher doses or with risk factors)</li>
          <li>Neuroleptic malignant syndrome (rare but serious: fever, rigidity, altered mental status, autonomic instability)</li>
          <li>Orthostatic hypotension (especially IM route)</li>
          <li>Tardive dyskinesia (with chronic use)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li><strong>Oral:</strong> Give with water; may take with or without food</li>
          <li><strong>IM injection:</strong> Deep IM into large muscle (gluteal or deltoid); monitor for hypotension and EPS</li>
          <li>Use lowest effective dose for shortest duration</li>
          <li>Avoid IV route in non-monitored settings (QTc/arrhythmia risk; follow institutional protocols if IV considered)</li>
          <li>Have benztropine/diphenhydramine available for acute dystonic reactions if possible</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Level of agitation/psychosis; de-escalate dose as symptoms improve</li>
          <li>Vital signs (BP, HR, temperature) especially after IM administration</li>
          <li>Extrapyramidal symptoms (muscle stiffness, tremor, restlessness, abnormal movements)</li>
          <li>ECG/QTc monitoring when feasible (especially if risk factors or higher doses)</li>
          <li>Watch for neuroleptic malignant syndrome (fever, rigidity, confusion, autonomic instability): stop drug and seek urgent help</li>
          <li>Sedation/fall risk (especially in elderly)</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Use for severe agitation/acute psychosis when de-escalation and non-pharmacologic approaches have failed or are unsafe</li>
          <li>Document mental status, vital signs, and clear indication before and after administration</li>
          <li>If limited monitoring capability: use conservatively and escalate/evacuate if severe behavioral disturbance or complications develop</li>
          <li>Consider need for benztropine or diphenhydramine onboard for acute dystonic reactions</li>
          <li>If patient on chronic haloperidol: verify dose and compliance history before additional dosing</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (haloperidol tablets): <a href="https://pdf.hres.ca/dpd_pm/00069651.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00069651.PDF</a></li>
          <li>Health Canada product monograph (haloperidol injection): <a href="https://pdf.hres.ca/dpd_pm/00069652.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00069652.PDF</a></li>
          <li>Medscape - Haloperidol: <a href="https://reference.medscape.com/drug/haldol-haloperidol-343010" target="_blank" rel="noopener">https://reference.medscape.com/drug/haldol-haloperidol-343010</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
